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Sumnary Rat monoclonal antibodies were prepared by immunising rats with human colorectal carcinoma
cell membranes and fusing splenic lymphocytes with a rat myeloma. Hybridoma supernatants were screened
by binding assays on membranes prepared from colorectal carcinoma tissue. One hybridoma supernatant,
containing a monoclonal antibody with high binding activity on malignant compared to normal colon
sections, was grown in large quantities in serum-free medium. After ammonium sulphate preciptation the
antibody was purified by ion-exchange chromatography and labelled with 1311. Radiolabelled antibody was
administered i.v. to 27 patients with colonic and other tumours. Scintigrams were obtained at 48h.
Computerised subtraction of the blood pool image revealed localised areas of uptake corresponding with
areas ofknown disease in 13/16 patients with colorectal carcinoma and 3/4 patients with breast cancer.
A major problem in the management of patients
with common solid tumours is the detection and
treatment of metastatic disease. Accurate staging is
important in selecting the best therapy for an
individual patient. Recent developments such as CT
scanning and ultrasound imaging have improved
the accuracy of staging. However, a significant
proportion of patients with solid tumours have
metastatic disease which currently remains
undetected at the time of initial therapy (Report of
Advisory Committee on Cancer Registration, 1980).
A possible tool for the detection and localisation
of metastatic disease is a suitably labelled tumour-
specific antibody, and already the use of
radiolabelled conventional antisera has had some
success (Mach et al., 1980; Dykes et al., 1980;
Goldenberg et al., 1980). Antisera with the
specificity required to discriminate between normal
and malignant tissue are difficult to produce. The
monoclonal antibody technology yields unlimited
quantities of pure reagents which avoid cross
reactions from contaminating antibodies and offer
the best hope ofproviding tumour-specific reagents.
There are already many reports of production of
monoclonal antibodies to human solid tumours
(Lennox & Sikora, 1982) with varying degrees of
specificity measured by cross reactions with other
tumours and normal tissue. Whether a particular
antibody will provide good tumour localisation
depends on several factors that can be measured in
vitro: the degree of cross reaction with normal
tissue; the Ig class of the antibody; its affinity for
the target antigen; and the amount of free antigen
in the serum potentially blocking its localisation.
Since predicting the possible effects in vivo of all
these factors is difficult, it is important to assess
monoclonal antibodies in carefully chosen clinical
situations. Such antibodies have other potential
advantages over conventional antisera as well as
their reproducible specificity. They can be prepared
as pure proteins, and thus the total load of labelled
foreign protein given to a patient is low.
Comparison can be made of antibodies of similar
specificity, but varying in antibody class or affinity.
Large batches of antibody can be produced
allowing the comparison of each preparation by
different investigators. Labelled mouse monoclonal
antibodies have been successfully used to localise
tumour deposits in immuno-suppressed mice
bearing human tumour xeongrafts (Levine et al.,
1980; Moshakis et al., 1981). There are, however,
few reports of the use of monoclonal antibodies for
localisation of tumours in patients where the
problems of cross reaction are completely different
(Mach et al., 1981; Epenetos et al., 1982). In this
paper we present the results of immunoscintigraphy
using a rat monoclonal antibody prepared against
colorectal carcinoma in patients with advanced
cancer.
Patients and methods
Monoclonal antibodies were prepared by
immunisng female DA rats on 3 occasions with a
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purified membrane preparation obtained from fresh
human colorectal carcinoma (Takei & Lennox,
unpublished). A suspension of splenic lymphocytes
was mixed with the rat myeloma line Y3.1.2.3.Ag
(Galfre et al., 1979) and fused in polyethylene
glycol (Hales, 1977). Hybrids were selected in HAT
medium (Miller & Ruddle, 1976) and cloned in
agar. Supernatants from cloned hybridoma were
screened by a solid phase radioimmunoassay for
binding to colon carcinoma membranes. Positive
supernatants were subsequently screened by
immunoperoxidase and immunofluorescence
techniques for binding to a range of normal and
malignant tissues (Finan et al., 1982). One antibody
was selected (YPC2/12.1) which showed strong
binding to all colorectal carcinomas tested but weak
binding to normal colon (Figure 1). Binding to
certain polymorphonuclear leucocytes was
observed. The antibody bound to purified
carcinoembryonic antigen (CEA), kindly provided
by Dr. G. Rogers. Immunoprecipitation with
lactoperoxidase-iodinated colorectal carcinoma cells
demonstrated a glycoprotein of 180Kd.
Immunohistology was performed with this antibody
on several tumour types. Binding was noted to all
colorectal cancers tested, and some breast and lung
cancers. No cytotoxicity to colorectal carcinoma
cells or leucocytes was observed with this antibody.
The antibody was of the IgG2a class. Ten litres of
supernatant was obtained by growing the
hybridoma in roller bottles in Iscove's (Flow
Laboratories) serum-free medium. Immunoglobulin
(Ig) concentrations of up to 100pgml- were
achieved. The Ig was precipitated with 50%
ammonium sulphate and purified on a DE52
(Whatman) ion exchange column. Purified antibody
was then iodinated with 1311 (Amersham) using a
modification of the chloramine T method. The
iodinated antibody (37mBcqmg-1 protein) was
filtered through a 22pm Millex filter to ensure
sterility and stored in 5% human serum at 4°C
prior to use within 2 weeks of preparation. The
purity of the final product was confirmed by
polyacrylamide gel electrophoresis in the presence
of sodium dodecyl sulphate (Figure 2).
Autoradiography showed heavy and light Ig chains
with no contaminating proteins. A direct
radioimmunoassay showed that binding activity to
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Figure 1 Immunoperoxidase staining of section of colorectal carcinoma with adjacent normal colon using
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Figure 2 Autoradiography of SDS-polyarcrylamide
gel of radiolabelled purified YPC2/12.1.
HT29 cells was maintained after labelling (Figure
3). Extensive studies on human colorectal tumour
xenografts growing in immuno-suppressed mice
revealed good tumour localisation with
tumour: muscle localisation ratios of 8: 1.
Ethical approval for the studies was given by the
Cambridge Health District Ethical Committee.
Twenty-seven patients with recurrent or metastatic
malignant disease gave informed consent to be
included in the study (Table). One mg of labelled
antibody was given by slow i.v. injection, in 20,ml
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Figure 3 Direct binding of radiolabelled YPC2/12.1
in preparation ready for patient administration to 105O
HT29 cells 0 0 and plastic plate *-* (serial
doubling dilutions).
of normal saline, 12h after the patients had
received 120mg potassium iodide by mouth to
block thyroid uptake of radio-iodine. Human
serum albumin labelled with 18.5mBcq of 99mTc
and 18.5 m Bcq of99mTc petechnetate was given 48 h
later in order to outline the free iodide and protein
distribution in the blood pool and scans obtained
30min after this second injection. Images were
obtained using an El-Scint rectilinear whole body
scanner and data were recorded on a Varian V77
computer which simultaneously recorded the 1311
iodine and the 99mTc distribution. The computer
subtracts a proportion of the 99mTc image from the
1311 image and produces an image which
represents, by means of colour variation, areas of
high concentration of 1311 labelled antibody.
Results
Antibody administration was well tolerated by all
patients and no adverse clinical reactions occurred
in any of the patients studied. One patient was
scanned twice using the same antibody without
incident. No change in peripheral blood counts
were noted after the study. In 13/16 patients with
colorectal carcinoma, antibody localisation which
closely correlated with areas of known disease was
detected. Figure 4 shows a chest X-ray and whole
body subtraction scan in a 63y-old patient who had
an anterior resection performed for a sigmoid
carcinoma 6mo previously. Large lung metastases
are evident on the chest X-ray and are cleary
shown on the subtraction scan in corresponding
positions. A deposit is also seen in the liver which
was confirmed by CT scan. Figure 5 shows the
antibody and CT scans of a patient with extensive
liver involvement by colorectal carcinoma. Clear
localisation of the metastases by the antibody is
demonstrated. Three patients with colorectal
carcinoma had scans which failed to show
localisation of the antibody within the tumour. In
one of these patients immunoperoxidase staining of
sections of the original tumour blocks showed only
weak binding of the antibody. The second patient
who failed to show localisation was receiving
palliative radiotherapy to painful pelvic recurrence
at the time of the scan which may have interfered
with the localisation of the antibody. No cause for
localisation failure in the third patient could be
found. In 3/13 patients in whom positive scans were
obtained, the extent of metastatic disease was
previously unsuspected by clinical examination.
Patient 4 was an example of this (Figure 6).
Subsequent conventional investigation (X-rays and
CT scans) confirmed the presence of metastases at
these sites (Figure 7). However the demonstration
of unsuspected metastases did not affect the clinical
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Table Details of patients receiving radiolabelled antibody
No. Age Sex
1 72 M
2 54 F
3 62 F
4 56 M
5 63 F
6 67 M
7 61 M
8 71 M
9 67 M
10 54 F
11 81 F
12 62 M
13 71 F
14 55 F
15 64 F
16 45 F
17 68 F
18 25 M
19 39 M
20 22 M
21 29 M
22 22 M
23 62 F
24 59 M
25 60 F
26 62 M
27 75 M
Primary
colon
colon
colon
colon
colon
colon
colon
colon
colon
colon
colon
colon
oesophagus
breast
breast
breast
breast
teratoma
teratoma
teratoma
teratoma
teratoma
colon
colon
lung
colon
colon
Sites of
known disease
pelvis
liver
lung
lung
paraaortic
pelvis, liver
pelvis
pelvis
pelvis
pelvis
pelvis
liver
mediastinum
lung
bone
chest wall
spine
paraaortic
paraaoritc
paraaortic
paraaortic
paraaortic
pelvis
pelvis
mediastinum
liver
pelvis
Figure 4 Chest X-ray and subtraction scan of patient
no. 3 (see table for details) showing lung metastases.
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Figure 5 Abdominal CT and subtraction scan of
patient 12 (see Table for details) showing liver
metastases.
Figure 6 Chest X-ray and subtraction scan of patient
4 (see Table for details) showing small 1 cm metastasis
in left lung.
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Figure 7 Abdominal CT scan of patient 4 (see Table for details)
metastases (top) and pelvic recurrence with bone infiltration (bottom).
management of these patients who were already Discussion
known to have extensive disease.
A total of 11 other patients were studied in order Monoclonal
to document the range of usefulness of this specific rea
particular antibody in localising various tumour therapy of
types. There appeared to be enough cross reaction computerise
with breast cancer to be useful but no clearly one 131I la
positive scans were obtained from patients with metastiatic
testicular neoplasms. carcinoma.
showing previously unsuspected liver
antibodies are promising potentially
gents for use in the diagnosis and
cancer. We have shown, using a
d subtraction technique, the ability of
belled monoclonal antibody to detect
disease in patients with colorectal
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an antibody is determined by the ratio of the
antibody distributing in the tumour to that in the
blood and adjacent tissue. This is influenced by
shed antigen concentration in the blood as well as
normal tissue cross reactions. For YPC2/12.1 there
is little cross reaction except with
polymorphonuclear leucocytes in the peripheral
blood and with cells of the granulocyte series in the
bone marrow. Despite this, localisation of
metastases was successful using subtraction
procedures to eliminate the image of blood borne
antibody. The inherent physical limitations of this
technique are compounded by both the poor
counting statistics and by the activity of the 131I in
the 99mTc photon peak. More precise definition
without subtraction may be obtained by use
of computerised emission tomography but this
requires complex equipment not widely available in
general hospitals. While subtraction procedures are
feasible for tumour localisation and can compensate
for some of the unwanted tissue localisation of the
labelled antibody, such undesired localisation could
not be tolerated if monoclonal antibodies are to be
used to deliver drugs or toxins for therapy. We are
currently searching for suitable monoclonal
antibodies for this purpose. In addition a
prospective study using YPC2/12.1 is being
undertaken in patients with colorectal carcinoma
prior to definitive surgery to assess the efficacy of
this technique compared with CT scanning for pre-
operative staging.
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